Although they only studied a small cohort of patients, Ruan and coworkers even suggested a BRAF V600E specific tumor suppressor function of MIG-6 in PTC, which was based on the observation that V600E mutated patients with high MIG-6 expression had a more favorable clinical course as those with low MIG-6 levels [26]. The gene discussed is BRAF; the disease is neoplasm.